A cancer vaccine developer has appointed a life sciences entrepreneur as chairman.
Dr. Wolfgang Oster is a managing partner for the life sciences fund at PolyTechnos, which focuses on investment in early stage, technology-oriented companies. Although the venture capital firm’s focus has been primarily on German companies, it has invested in several U.S.-based life sciences businesses. Oster worked for several years at U.S. Bioscience, which was later acquired by Maryland-based MedImmune in 1999.
Oster also serves as board member for some regional companies including Genossis, Oncoceutics and Provid.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Last month, Berwyn, Pennsylvania-based Formula Pharmaceuticals added pharmaceutical veteran Martyn Greenacre to its board and is in the midst of raising $13 million to advance its oncology therapeutic through phase 2 clinical trials.
The company’s vaccine is designed to be used during first remission for acute myeloid leukemia and other aggressive cancers.
